Nemtabrutinib Clinical Trials (2026): 21 Studies for Chronic Lymphocytic Leukemia & Healthy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
21 Nemtabrutinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 13 indications (including Chronic Lymphocytic Leukemia & Healthy) and 3,453 total planned enrollment. 3 Phase 3 Nemtabrutinib trials and 7 Phase 2 are listed. 9 Nemtabrutinib clinical trials are actively recruiting at 59 U.S. sites across 24 states. Most recent activity: NCT05947851 (Jul 2035).
Where to Participate: All Nemtabrutinib Trial Sites in the U.S. (59 sites across 24 states)
Every actively recruiting Nemtabrutinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | USA Mitchell Cancer Institute ( Site 0014) | Mobile36604 | NCT06136559 | Map |
| AZ | Banner MD Anderson Cancer Center ( Site 0059) | Gilbert85234 | NCT06136559 | Map |
| AZ | Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) | Phoenix85006 | NCT06136559 | Map |
| AR | Highlands Oncology Group ( Site 2728) | Springdale72762 | NCT04728893 | Map |
| AR | Highlands Oncology Group ( Site 5405) | Springdale72762 | NCT05947851 | Map |
| CA | Alta Bates Summit Medical Center ( Site 0004) | Berkeley94704 | NCT06136559 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06572618 | Map |
| CA | Moores Cancer Center ( Site 0003) | La Jolla92093-0698 | NCT06136559 | Map |
| CA | University of California San Diego Moores Cancer Center ( Site 2717) | La Jolla92093-0698 | NCT04728893 | Map |
| CA | MemorialCare Health System - Long Beach Medical Center ( Site 5421) | Long Beach90806 | NCT05947851 | Map |
| CA | Care Access - South Pasadena ( Site 0070) | Pasadena91105 | NCT06136559 | Map |
| CO | Colorado Blood Cancer Institute ( Site 2726) | Denver80218 | NCT04728893 | Map |
| CO | Saint Joseph Hospital ( Site 0026) | Denver80218 | NCT06136559 | Map |
| CO | Lutheran Medical Center ( Site 0027) | Golden80401 | NCT06136559 | Map |
| CO | Intermountain Health St. Mary's Regional Hospital ( Site 0025) | Grand Junction81501 | NCT06136559 | Map |
| CT | Eastern CT Hematology & Oncology Associates ( Site 0033) | Norwich06360 | NCT06136559 | Map |
| FL | Clermont Oncology Center ( Site 0046) | Clermont34711 | NCT06136559 | Map |
| FL | Florida Cancer Specialists - South ( Site 7001) | Fort Myers33901 | NCT06136559 | Map |
| FL | Clinical Pharmacology of Miami ( Site 0003) | Miami33172 | NCT06442436 | Map |
| FL | Orlando Clinical Research Center ( Site 0001) | Orlando32809 | NCT06442436 | Map |
| FL | Memorial Hospital West ( Site 5410) | Pembroke Pines33028 | NCT05947851 | Map |
| FL | Florida Cancer Specialists - East ( Site 7002) | West Palm Beach33401 | NCT06136559 | Map |
| IN | Parkview Research Center at Parkview Regional Medical Center ( Site 0002) | Fort Wayne46845 | NCT06136559 | Map |
| IA | University of Iowa Health Care. ( Site 0017) | Waukee50263 | NCT06136559 | Map |
| IA | University of Iowa Health Care. ( Site 0057) | Waukee50263 | NCT06136559 | Map |
| KY | Saint Elizabeth Healthcare ( Site 0041) | Edgewood41017 | NCT06136559 | Map |
| MI | Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) | Grand Rapids49503 | NCT06136559 | Map |
| MN | Regions Hospital ( Site 0042) | Saint Louis Park55416 | NCT06136559 | Map |
| MO | MidAmerica Cancer Care, LLC ( Site 0043) | Kansas City64132 | NCT06136559 | Map |
| MT | Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052) | Billings59102 | NCT06136559 | Map |
| NJ | Astera Cancer Care ( Site 2732) | East Brunswick08816 | NCT04728893 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) | Hackensack07601 | NCT06136559 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) | Hackensack07601 | NCT04728893 | Map |
| NY | New York Oncology Hematology, P.C. ( Site 0069) | Albany12208 | NCT06136559 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06863402 | Map |
| NY | Roswell Park Cancer Institute ( Site 0023) | Buffalo14263 | NCT06136559 | Map |
| NY | RPCI Oncology, PC- Northtowns ( Site 0061) | Williamsville14221 | NCT06136559 | Map |
| NC | Carolina Oncology Specialists, PA ( Site 0054) | Charlotte28207 | NCT06136559 | Map |
| NC | Southeastern Medical Oncology Center ( Site 0049) | Goldsboro27534 | NCT06136559 | Map |
| OR | Oregon Health and Science University ( Site 5425) | Portland97239-3011 | NCT05947851 | Map |
| PA | Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002) | Broomall19008 | NCT06136559 | Map |
| PA | Cancer Care Associates Of York ( Site 0005) | York17403 | NCT06136559 | Map |
| TN | Tennessee Oncology-Chattanooga ( Site 0045) | Chattanooga37404 | NCT06136559 | Map |
| TN | Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) | Nashville37203 | NCT06136559 | Map |
| TX | Texas Oncology - Central/South Texas ( Site 8008) | Austin78705 | NCT06136559 | Map |
| TX | UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730) | Dallas75390 | NCT04728893 | Map |
| TX | The Center for Cancer and Blood Disorders ( Site 0032) | Fort Worth76104 | NCT06136559 | Map |
| TX | Texas Liver Institute ( Site 0002) | San Antonio78215 | NCT06442436 | Map |
| TX | Texas Oncology - San Antonio ( Site 8006) | San Antonio78217 | NCT06136559 | Map |
| TX | Texas Oncology - Northeast Texas ( Site 8012) | Tyler75702 | NCT06136559 | Map |
| VA | University of Virginia Cancer Center ( Site 0040) | Charlottesville22903 | NCT06136559 | Map |
| VA | Inova Schar Cancer Institute ( Site 0015) | Fairfax22031 | NCT06136559 | Map |
| VA | Virginia Commonwealth University (VCU) Medical Center ( Site 0030) | Richmond23298 | NCT06136559 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07194980 | Map |
| WA | Medical Oncology Associates (Summit Cancer Centers) ( Site 2710) | Spokane99208 | NCT04728893 | Map |
| WA | Medical Oncology Associates, PS ( Site 5406) | Spokane99208 | NCT05947851 | Map |
| WA | Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010) | Spokane99208 | NCT06136559 | Map |
| WI | SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) | Madison53715 | NCT06136559 | Map |
| WI | University Hospital and UW Health Clinics ( Site 0006) | Madison53792 | NCT06136559 | Map |
Nemtabrutinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | 8 | 10 | |
| P1/P2 | 1 | 1 | |||
| P2 | 4 | 1 | 2 | 7 | |
| P3 | 2 | 1 | 3 |
Recruiting Nemtabrutinib clinical trials (9)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05947851 | VRA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | Aug 2023 |
| NCT06136559 | MK-1026A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | P3 | Chronic Lymphocytic Leukemia | 1,200 | Dec 2023 |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | P2 | Richter Syndrome | 32 | Jun 2026 |
| NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 20 | Jul 2026 |
| NCT04728893 | MK-1026Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | P2 | Hematologic Malignancies | 490 | Apr 2021 |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | P2 | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 35 | Dec 2026 |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | Chronic Lymphocytic Leukemia | 25 | May 2026 |
| NCT06572618 | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 27 | Jan 2025 |
| NCT06442436 | MK-1026-015A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) | P1 | Hepatic Impairment (HI) | 32 | Jul 2024 |
Nemtabrutinib clinical trials by indication
Healthy (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07232589 | MK-1026-022 | P1 | completed | A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) |
| NCT06772818 | MK-1026 | P1 | completed | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) |
| NCT06625827 | MK-1026 | P1 | completed | A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) |
| NCT06688045 | MK-1026-013 | P1 | completed | A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) |
| NCT06772805 | MK-1026 | P1 | completed | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) |
| NCT06698016 | MK-1026-014 | P1 | completed | A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) |
Chronic Lymphocytic Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06136559 | MK-1026 | P3 | recruiting | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) |
| NCT05624554 | — | P3 | active not recruiting | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) |
| NCT05458297 | MK-2140 | P2 | active not recruiting | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) |
| NCT07557056 | — | P2 | not yet recruiting | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07583810 | — | P2 | not yet recruiting | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma |
Richter Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06863402 | — | P2 | recruiting | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype |
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07194980 | — | P2 | recruiting | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06572618 | — | P2 | recruiting | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma |
Hepatic Impairment (HI) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06442436 | MK-1026-015 | P1 | recruiting | A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) |
Hematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06586671 | MK-1026 | P1 | completed | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) |
Leukemia, Lymphocytic, Chronic, B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05947851 | VR | P3 | recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). |
Mature B-cell Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05673460 | MK-1026-002 | P1 | completed | A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) |
Hematological Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05347225 | MK-1026 | P1 | active not recruiting | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) |
Hematologic Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04728893 | MK-1026 | P2 | recruiting | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) |
Lymphoma, B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03162536 | MK-1026 | P1/P2 | active not recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) |
Nemtabrutinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VR | NCT05947851 | P3 | recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 735 | — |
| MK-1026 | NCT06136559 | P3 | recruiting | Chronic Lymphocytic Leukemia | 1,200 | — |
| MK-2140 | NCT05458297 | P2 | active not recruiting | Chronic Lymphocytic Leukemia | 189 | — |
| MK-1026 | NCT04728893 | P2 | recruiting | Hematologic Malignancies | 490 | — |
All Nemtabrutinib trials (21)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05947851 | VR | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | P3 | recruiting | 735 | Merck Sharp & Dohme LLC | Aug 2023 |
| NCT06136559 | MK-1026 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | P3 | recruiting | 1,200 | Merck Sharp & Dohme LLC | Dec 2023 |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | P3 | active not recruiting | 300 | Merck Sharp & Dohme LLC | Mar 2023 | |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | P2 | recruiting | 32 | Roswell Park Cancer Institute | Jun 2026 | |
| NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | P2 | recruiting | 20 | Fred Hutchinson Cancer Center | Jul 2026 | |
| NCT05458297 | MK-2140 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | P2 | active not recruiting | 189 | Merck Sharp & Dohme LLC | Jul 2022 |
| NCT04728893 | MK-1026 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | P2 | recruiting | 490 | Merck Sharp & Dohme LLC | Apr 2021 |
| NCT05347225 | MK-1026 | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | P1 | active not recruiting | 12 | Merck Sharp & Dohme LLC | Jun 2022 |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | P2 | not yet recruiting | 35 | City of Hope Medical Center | Dec 2026 | |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P2 | not yet recruiting | 25 | Jennifer Woyach | May 2026 | |
| NCT03162536 | MK-1026 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | P1/P2 | active not recruiting | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Jun 2017 |
| NCT06572618 | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | P2 | recruiting | 27 | City of Hope Medical Center | Jan 2025 | |
| NCT06442436 | MK-1026-015 | A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) | P1 | recruiting | 32 | Merck Sharp & Dohme LLC | Jul 2024 |
| NCT07232589 | MK-1026-022 | A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) | P1 | completed | 26 | Merck Sharp & Dohme LLC | Dec 2025 |
| NCT05673460 | MK-1026-002 | A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) | P1 | completed | 7 | Merck Sharp & Dohme LLC | Feb 2023 |
| NCT06772818 | MK-1026 | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) | P1 | completed | 20 | Merck Sharp & Dohme LLC | Oct 2023 |
| NCT06625827 | MK-1026 | A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) | P1 | completed | 24 | Merck Sharp & Dohme LLC | Nov 2023 |
| NCT06688045 | MK-1026-013 | A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) | P1 | completed | 15 | Merck Sharp & Dohme LLC | Oct 2023 |
| NCT06772805 | MK-1026 | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) | P1 | completed | 18 | Merck Sharp & Dohme LLC | Jul 2023 |
| NCT06586671 | MK-1026 | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) | P1 | completed | 40 | Merck Sharp & Dohme LLC | Aug 2023 |
| NCT06698016 | MK-1026-014 | A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) | P1 | completed | 16 | Merck Sharp & Dohme LLC | Jul 2023 |
Nemtabrutinib clinical trials: frequently asked questions
- How many Nemtabrutinib clinical trials are there?
- 21 Nemtabrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 8 are marked completed.
- Are Nemtabrutinib clinical trials recruiting in 2026?
- Yes — 7 Nemtabrutinib trials are actively recruiting in 2026, with 59 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Nemtabrutinib being studied for?
- Nemtabrutinib is being studied for Chronic Lymphocytic Leukemia, Healthy, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma and 30 more. The trials are grouped by indication on this page.
- What phase is Nemtabrutinib in?
- Nemtabrutinib clinical trials span 3 Phase 3, 7 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Nemtabrutinib clinical trials?
- The lead sponsor across the most Nemtabrutinib trials is Merck Sharp & Dohme LLC, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nemtabrutinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: